Dose Escalation With SIB to Intraprostatic/Lymphatic GTV in High Risk Prostate Cancer
NCT ID: NCT01962324
Last Updated: 2024-03-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
85 participants
INTERVENTIONAL
2015-03-31
2023-05-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
NCT04486755
Intensity Modulated Radiation Therapy (IMRT) Pelvic Nodes Prostate
NCT00915122
Tumor-directed Radiation Therapy for Patients With the Highest Risk Category of Localized Prostate Cancer
NCT06220435
High-Dose Lymph Node Intensity Modulated Radiation Therapy and Hypofractionated Prostate (SIB)
NCT02177292
Hypofractionated Radiotherapy With a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer
NCT07325721
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SIB Dose-Escalation radiotherapy
Simultaneous integrated boost to intraprostatatic tumor and lymph nodes
SIB Dose-Escalation Radiotherapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SIB Dose-Escalation Radiotherapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written informed consent
* \> 18 years
* Fiducial gold markers implanted in the prostate (min 3)
Exclusion Criteria
* WHO PS\>1
* Previous pelvic irradiation
* TURP within 6 months
* IPSS \>19
* Metastatic disease in skeleton, parenchymal organs or lymph nodes outside the pelvis
* Creatinin clearance \< 30ml/min according to http://www.fass.se/LIF/produktfakta/kreatinin.jsp
18 Years
80 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Umeå University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Camilla Thellenberg Karlsson
MD, PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Camilla Thellenberg Karlsson, MD
Role: PRINCIPAL_INVESTIGATOR
Umea University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Umeå University, Cancercenter
Umeå, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PARAPLY-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.